C-TAK1 Inhibitors
Chemical inhibitors of C-TAK1 include a range of compounds that target various kinases and signaling molecules upstream of this protein, thereby diminishing its activity through a cascade effect. SP600125, a JNK inhibitor, can lead to reduced phosphorylation and subsequent activation of C-TAK1 by impeding one of the upstream kinases that facilitate its activation. Similarly, SB203580 and BIRB 0796 both serve as p38 MAP kinase inhibitors, and by curtailing the activity of p38, they can decrease the activation of C-TAK1, which is known to function in tandem with p38 in stress response signaling. PI3K inhibitors such as Wortmannin and LY294002 can reduce AKT activation, which in turn can lower the phosphorylation and subsequent activation of C-TAK1. By targeting PI3K, these inhibitors can suppress one of the pathways that contribute to the functional activation of C-TAK1.
Continuing with the molecular inhibition of C-TAK1, PD98059 and U0126, both MEK inhibitors, as well as SL327, lessen the activation of ERK, another kinase that participates in cross-talk with C-TAK1, which can result in a decrease in C-TAK1 activity. Rapamycin, an mTOR inhibitor, can lead to decreased C-TAK1 activity by reducing signaling demands that may otherwise engage and activate C-TAK1. PP2, as an Src family kinase inhibitor, can also lead to reduced C-TAK1 activity by preventing the phosphorylation of downstream targets, including C-TAK1. Furthermore, Sorafenib and Sunitinib, which target several kinases including RAF kinases and receptor tyrosine kinases respectively, can lead to reduced activation of kinases in the pathways where C-TAK1 is involved, thereby decreasing C-TAK1's overall activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor that targets JNK, which is upstream of C-TAK1 in the MAPK signaling pathway. Inhibition of JNK can lead to reduced phosphorylation and activation of C-TAK1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole compound that inhibits p38 MAP kinase, which works synergistically with C-TAK1 in stress response pathways. Inhibiting p38 can decrease the activation of C-TAK1 by limiting upstream signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal furan derivative that inhibits PI3K, which indirectly can reduce AKT activation, a kinase that may phosphorylate and activate C-TAK1, leading to its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a flavonoid derivative and another PI3K inhibitor that, like Wortmannin, can lead to reduced AKT activity and subsequently lower the phosphorylation and activation of C-TAK1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that inhibits MEK, which is upstream of ERK in the MAPK pathway. ERK has been known to cross-talk with C-TAK1 signaling, and its inhibition can lead to reduced C-TAK1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR, which is involved in cell growth and proliferation pathways that may engage C-TAK1. Inhibition of mTOR can lead to decreased C-TAK1 activity due to reduced signaling demand. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and by inhibiting these kinases, it can decrease ERK activation and thus lower the potential for C-TAK1 activating cross-talk within MAPK signaling pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, which can lead to reduced phosphorylation of downstream targets, potentially including C-TAK1, thus functionally inhibiting C-TAK1 activity. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 0796 is a selective p38 MAPK inhibitor, which by inhibiting p38 MAPK, can reduce the associated phosphorylation and activation of C-TAK1 in cellular stress response pathways. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK1/2, similar to U0126, and can decrease the activation of ERK, which in turn may reduce the activation of C-TAK1 due to less cross-talk within the MAPK pathways. | ||||||